6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met

Biochemical and Biophysical Research Communications

Volumn 439, Issue 2, 2013, Pages 247-251

  Chan, Barden ^a   VanderLaan, Paul A ^a   Sukhatme, Vikas P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

6 Phosphogluconate dehydrogenase; C Met; Glucose metabolism; Glycolytic tumors; Migration; TPR cMet

Indexed keywords

PHOSPHOGLUCONATE DEHYDROGENASE; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL;

6-PHOSPHOGLUCONATE; 6-PHOSPHOGLUCONATE DEHYDROGENASE; 6PGD; C-MET; FBS; FETAL BOVINE SERUM; GLUCOSE METABOLISM; GLYCOLYTIC TUMORS; HGF; HUMAN HEPATOCYTE GROWTH FACTOR; LACTATE DEHYDROGENASE A; LDHA; MIGRATION; PENTOSE PHOSPHATE PATHWAY; PKM2; PPP; PYRUVATE KINASE M2; TPR-CMET;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG; LUNG NEOPLASMS; MICE; NEOPLASM STAGING; PHOSPHOGLUCONATE DEHYDROGENASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UP-REGULATION;

MUS;

EID: 84884287630     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.048     Document Type: Article

References (23)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
3. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
4. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
5. Hitosugi T., Zhou L., Elf S., Fan J., Kang H.B., Seo J.H., Shan C., Dai Q., Zhang L., Xie J., Gu T.L., Jin P., Aleckovic M., LeRoy G., Kang Y., Sudderth J.A., DeBerardinis R.J., Luan C.H., Chen G.Z., Muller S., Shin D.M., Owonikoko T.K., Lonial S., Arellano M.L., Khoury H.J., Khuri F.R., Lee B.H., Ye K., Boggon T.J., Kang S., He C., Chen J. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 2012, 22:585-600.
6. Yi W., Clark P.M., Mason D.E., Keenan M.C., Hill C., Goddard W.A., Peters E.C., Driggers E.M., Hsieh-Wilson L.C. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 2012, 337:975-980.
7. Xie H., Valera V.A., Merino M.J., Amato A.M., Signoretti S., Linehan W.M., Sukhatme V.P., Seth P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer Ther. 2009, 8:626-635.
8. Muller F.L., Colla S., Aquilanti E., Manzo V.E., Genovese G., Lee J., Eisenson D., Narurkar R., Deng P., Nezi L., Lee M.A., Hu B., Hu J., Sahin E., Ong D., Fletcher-Sananikone E., Ho D., Kwong L., Brennan C., Wang Y.A., Chin L., DePinho R.A. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 2012, 488:337-342.
9. Mathupala S.P., Ko Y.H., Pedersen P.L. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin. Cancer Biol. 2009, 19:17-24.
10. Ritterson Lew C., Tolan D.R. Targeting of several glycolytic enzymes using RNA interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism. J. Biol. Chem. 2012, 287:42554-42563.
11. Meadows A.L., Kong B., Berdichevsky M., Roy S., Rosiva R., Blanch H.W., Clark D.S. Metabolic and morphological differences between rapidly proliferating cancerous and normal breast epithelial cells. Biotechnol. Prog. 2008, 24:334-341.
12. Richardson A.D., Yang C., Osterman A., Smith J.W. Central carbon metabolism in the progression of mammary carcinoma. Breast Cancer Res. Treat. 2008, 110:297-307.
13. Sukhatme V.P., Chan B. Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence. FEBS Lett. 2012, 586:2389-2395.
14. Gupta P.B., Kuperwasser C., Brunet J.P., Ramaswamy S., Kuo W.L., Gray J.W., Naber S.P., Weinberg R.A. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 2005, 37:1047-1054.
15. Fisher C.J., Gillett C.E., Vojtesek B., Barnes D.M., Millis R.R. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br. J. Cancer 1994, 69:26-31.
16. Adams E.J., Green J.A., Clark A.H., Youngson J.H. Comparison of different scoring systems for immunohistochemical staining. J. Clin. Pathol. 1999, 52:75-77.
17. Brocklehurst D., Champion A.E., Cheek T.R., Dewhurst D.G. The value of 6-phosphogluconate dehydrogenase (6-PGDH) activity as a marker of tumour cellularity and prognostic indicator in primary breast cancer. Tumour Biol. 1986, 7:99-104.
18. Longati P., Bardelli A., Ponzetto C., Naldini L., Comoglio P.M. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 1994, 9:49-57.
19. Yamada T., Matsumoto K., Wang W., Li Q., Nishioka Y., Sekido Y., Sone S., Yano S. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin. Cancer Res. 2010, 16:174-183.
20. Park M., Dean M., Cooper C.S., Schmidt M., O'Brien S.J., Blair D.G., Vande Woude G.F. Mechanism of met oncogene activation. Cell 1986, 45:895-904.
21. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4:915-925.
22. Hitosugi T., Kang S., Vander Heiden M.G., Chung T.W., Elf S., Lythgoe K., Dong S., Lonial S., Wang X., Chen G.Z., Xie J., Gu T.L., Polakiewicz R.D., Roesel J.L., Boggon T.J., Khuri F.R., Gilliland D.G., Cantley L.C., Kaufman J., Chen J. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2:ra73.
23. Fan J., Hitosugi T., Chung T.W., Xie J., Ge Q., Gu T.L., Polakiewicz R.D., Chen G.Z., Boggon T.J., Lonial S., Khuri F.R., Kang S., Chen J. Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol. Cell. Biol. 2011, 31:4938-4950.